$937.00
In EU: Product is CE Marked. Health Canada Licensed. See website for more details.
PRODUCT DESCRIPTION
In EU: This Product is CE Marked. Health Canada Licensed. Enzyme immuno-assay designed for measuring globally all heparin-dependent antibodies, whether the isotype is: IgG, IgM and IgA, in human plasma or serum, or in any biological fluid where these antibodies must be measured. This assay is proposed as screening, as an early identification of heparin treated patients presenting a risk to develop HIT or HITT. This assay measures the whole of antibodies. It offers the highest sensitivity as all isotypes are detected. It is the preferred assay when an early detection of heparin dependent antibodies is required for assessing the development risk of HIT/HITT.
In EU: Product is CE Marked. Health Canada Licensed. See website for more details.
PRODUCT CHARACTERISTICS
Total Assay Time: 2 hr 15 min
Cut Off: A450 ≥ 0.50
Dynamic Range: A450 up to 3.0
Intra-Assay CV: 4 to 6%
Inter-Assay CV: 5 to 8%
PRODUCT COMPONENTS
Micro ELISA Plate (12 strips of 8 wells)
2x HIA Sample Diluent.
3x HIA IgGAM Positive Control.
3x Negative Control.
3x Platelet Lysate.
3x Anti-IgG (Fcγ)-IgM (µ)-IgA(α)-HRP IC
1x Conjugate Diluent.
1x Wash Solution.
1x TMB.
1 x 0.45M Sulfuric Acid.
Video of Product Components
PRODUCT APPLICATION
Assessment of the risk to develop HIT/HITT, in patients treated with heparins (Unfractionated or LMWH): presence of antibodies is a risk indicator for development of HIT/HITT.
Clinical suspicion of HIT during heparin therapy.
MSDS Documents
IFU Documents
